TLC BioSciences Statistics
Total Valuation
TLC BioSciences has a market cap or net worth of TWD 28.85 billion. The enterprise value is 29.11 billion.
| Market Cap | 28.85B |
| Enterprise Value | 29.11B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
TLC BioSciences has 133.56 million shares outstanding.
| Current Share Class | 133.56M |
| Shares Outstanding | 133.56M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 24.45% |
| Owned by Institutions (%) | n/a |
| Float | 88.80M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 322.56 |
| PB Ratio | -7.84 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.18
| Current Ratio | 0.18 |
| Quick Ratio | 0.14 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.06 |
| Interest Coverage | -5.07 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -21.30% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 17.76% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.05 |
| Inventory Turnover | 0.30 |
Taxes
In the past 12 months, TLC BioSciences has paid 4.61 million in taxes.
| Income Tax | 4.61M |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 48.38 |
| Average Volume (20 Days) | 298,330 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, TLC BioSciences had revenue of TWD 89.44 million and -653.25 million in losses. Loss per share was -7.84.
| Revenue | 89.44M |
| Gross Profit | 73.93M |
| Operating Income | -639.05M |
| Pretax Income | -648.64M |
| Net Income | -653.25M |
| EBITDA | -571.17M |
| EBIT | -639.05M |
| Loss Per Share | -7.84 |
Balance Sheet
The company has 694.74 million in cash and 955.97 million in debt, with a net cash position of -261.23 million or -1.96 per share.
| Cash & Cash Equivalents | 694.74M |
| Total Debt | 955.97M |
| Net Cash | -261.23M |
| Net Cash Per Share | -1.96 |
| Equity (Book Value) | -3.68B |
| Book Value Per Share | -44.16 |
| Working Capital | -4.17B |
Cash Flow
In the last 12 months, operating cash flow was -347.17 million and capital expenditures -117.83 million, giving a free cash flow of -464.99 million.
| Operating Cash Flow | -347.17M |
| Capital Expenditures | -117.83M |
| Depreciation & Amortization | 67.88M |
| Net Borrowing | -52.79M |
| Free Cash Flow | -464.99M |
| FCF Per Share | -3.48 |
Margins
| Gross Margin | 82.66% |
| Operating Margin | -714.51% |
| Pretax Margin | -725.24% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TLC BioSciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -2.26% |
| FCF Yield | -1.61% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TLC BioSciences has an Altman Z-Score of -16.9 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -16.9 |
| Piotroski F-Score | 1 |